Quarterly report · Q1
2160.TEDINET S100TFYV
Period2024-01-01 → 2024-03-31
Filed2024-05-15
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥5.9bn | 2024-01-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥26.0bn | 2023-01-01 → 2023-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥4.2bn | 2023-01-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥2.3bn | 2024-01-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥398m | 2023-01-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥1.8bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥12.6bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | −¥65m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥1.5bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥8.1bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | −¥3m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥1.3bn | 2024-01-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥9.5bn | 2023-01-01 → 2023-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | −¥342m | 2023-01-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥65.6bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥62.4bn | at 2023-12-31 | Cons. | Assets IFRS |
| Total assets | ¥34.1bn | at 2023-03-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥27.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥26.3bn | at 2023-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥37.8bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥36.1bn | at 2023-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥19.8bn | at 2022-12-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥34.6bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥33.8bn | at 2023-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥21.2bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥20.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.6bn | at 2023-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥10.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥11.0bn | at 2022-12-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥350m | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥6.5bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥710m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥1.8bn | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥6.8bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥1.2bn | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥88m | 2024-01-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥10.7bn | 2023-01-01 → 2023-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥52m | 2023-01-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥29.17 | 2024-01-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥169.5 | 2023-01-01 → 2023-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥-0.06 | 2023-01-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥28 | 2024-01-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥165.56 | 2023-01-01 → 2023-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥-0.06 | 2023-01-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.2% | at 2023-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.2% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥1.3bn |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥539m |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue external | 2024-01-01 → 2024-03-31 | ¥4.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | segment profit | 2024-01-01 → 2024-03-31 | ¥1.7bn |
| —segment total | revenue | 2024-01-01 → 2024-03-31 | ¥5.9bn |
| —segment total | revenue external | 2024-01-01 → 2024-03-31 | ¥5.9bn |
| —segment total | segment profit | 2024-01-01 → 2024-03-31 | ¥2.3bn |
| Reconciling Itemsreconciling | revenue | 2023-01-01 → 2023-03-31 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-01-01 → 2023-03-31 | −¥23m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥623m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥600m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥23m |
| jpcrp040300-q1r_E05712-000Medical Devicereportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥248m |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue | 2023-01-01 → 2023-03-31 | ¥3.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | revenue external | 2023-01-01 → 2023-03-31 | ¥3.6bn |
| jpcrp040300-q1r_E05712-000Pharmaceuticalreportable segment | segment profit | 2023-01-01 → 2023-03-31 | ¥149m |
| —segment total | revenue | 2023-01-01 → 2023-03-31 | ¥4.2bn |
| —segment total | revenue external | 2023-01-01 → 2023-03-31 | ¥4.2bn |
| —segment total | revenue intersegment | 2023-01-01 → 2023-03-31 | ¥23m |
| —segment total | segment profit | 2023-01-01 → 2023-03-31 | ¥398m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 599
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 49893243 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 49983243 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 49893243 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 49983243 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 13500 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 49829400 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 498294 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 14343 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 49857243 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 498294 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 13500 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 13500 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0002 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 13500 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 13500 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0002 | |
| Property plant and equipment IFRS | Prior1YearInstant | 5238673000 | JPY |
| Property plant and equipment IFRS | CurrentQuarterInstant | 5503417000 | JPY |
| Right of use assets IFRS | Prior1YearInstant | 814513000 | JPY |
| Right of use assets IFRS | CurrentQuarterInstant | 780770000 | JPY |
| Goodwill IFRS | Prior1YearInstant | 17261275000 | JPY |
| Goodwill IFRS | CurrentQuarterInstant | 18545037000 | JPY |
| Intangible assets IFRS | Prior1YearInstant | 3690331000 | JPY |
| Intangible assets IFRS | CurrentQuarterInstant | 4028271000 | JPY |
| Investments accounted for using equity method IFRS | Prior1YearInstant | 360821000 | JPY |
| Investments accounted for using equity method IFRS | CurrentQuarterInstant | 382398000 | JPY |
| Deferred tax assets IFRS | Prior1YearInstant | 304436000 | JPY |
| Deferred tax assets IFRS | CurrentQuarterInstant | 261129000 | JPY |
| Other financial assets nca IFRS | Prior1YearInstant | 3793224000 | JPY |
| Other financial assets nca IFRS | CurrentQuarterInstant | 4094138000 | JPY |
| Other non current assets nca IFRS | Prior1YearInstant | 23811000 | JPY |
| Other non current assets nca IFRS | CurrentQuarterInstant | 25420000 | JPY |
| Non current assets IFRS | Prior1YearInstant | 31487087000 | JPY |
| Non current assets IFRS | CurrentQuarterInstant | 33620583000 | JPY |
| Inventories ca IFRS | Prior1YearInstant | 2330622000 | JPY |
| Inventories ca IFRS | CurrentQuarterInstant | 2496616000 | JPY |
| Trade and other receivables ca IFRS | Prior1YearInstant | 3973476000 | JPY |
| Trade and other receivables ca IFRS | CurrentQuarterInstant | 4489831000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 1577274000 | JPY |
| Other financial assets ca IFRS | CurrentQuarterInstant | 3180744000 | JPY |
| Other current assets ca IFRS | Prior1YearInstant | 1392881000 | JPY |
| Other current assets ca IFRS | CurrentQuarterInstant | 1470273000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 21633028000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 20342064000 | JPY |
| Current assets IFRS | Prior1YearInstant | 30907282000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |